| Literature DB >> 25886267 |
Ulises Garza-Ramos1, Jesús Silva-Sánchez2, Esperanza Martínez-Romero3, Perla Tinoco4, Marisol Pina-Gonzales5, Humberto Barrios6, Jesús Martínez-Barnetche7, Rosa Elena Gómez-Barreto8, Juan Tellez-Sosa9.
Abstract
BACKGROUND: Klebsiella variicola was very recently described as a new bacterial species and is very closely related to Klebsiella pneumoniae; in fact, K. variicola isolates were first identified as K. pneumoniae. Therefore, it might be the case that some isolates, which were initially classified as K. pneumoniae, are actually K. variicola. The aim of this study was to devise a multiplex-PCR probe that can differentiate isolates from these sister species. RESULT: This work describes the development of a multiplex-PCR method to identify K. variicola. This development was based on sequencing a K. variicola clinical isolate (801) and comparing it to other K. variicola and K. pneumoniae genomes. The phylogenetic analysis showed that K. variicola isolates form a monophyletic group that is well differentiated from K. pneumoniae. Notably, the isolate K. pneumoniae 342 and K. pneumoniae KP5-1 might have been misclassified because in our analysis, both clustered with K. variicola isolates rather than with K. pneumoniae. The multiplex-PCR (M-PCR-1 to 3) probe system could identify K. variicola with high accuracy using the shared unique genes of K. variicola and K. pneumoniae genomes, respectively. M-PCR-1 was used to assay a collection of multidrug-resistant (503) and antimicrobial-sensitive (557) K. pneumoniae clinical isolates. We found K. variicola with a prevalence of 2.1% (23/1,060), of them a 56.5% (13/23) of the isolates were multidrug resistant, and 43.5% (10/23) of the isolates were antimicrobial sensitive. The phylogenetic analysis of rpoB of K. variicola-positive isolates identified by multiplex-PCR support the correct identification and differentiation of K. variicola from K. pneumoniae clinical isolates.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25886267 PMCID: PMC4361152 DOI: 10.1186/s12866-015-0396-6
Source DB: PubMed Journal: BMC Microbiol ISSN: 1471-2180 Impact factor: 3.605
Amplification conditions, oligonucleotide combinations, sequence and amplification fragment of multiplex-PCR for identification
|
|
|
| |||||
|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
| ||
| phosphohydrolase | phosphoglycerate mutase | phosphopentane phosphatase ( | |||||
| 1 | M-PCR-1 | KP888-F: AAGCAAGCCAGAACAGAAAG | 888 | KV770-F: TCCCGAGGTTCACATTTCC | 449 | KmtnC-F: CCGCCGACCTTATCACTAC | 340 |
| KP888-R: ACTTCGGTTTTATCCAGGTC | KV770-R: AGCGGGTGAACGTCGATAC | KmtnC-R: AGCGGGTGAACGTCGATAC | |||||
| transferase ( | N-acetyltransferase | phosphopentane phosphatase ( | |||||
| 1 | M-PCR-2 | KP878-F: ACCGATAACCAGCCTGACTT | 878 | KV1615-F: ACACAACATTTCAGGCGGCT | 499 | KmtnC-F: CCGCCGACCTTATCACTAC | 340 |
| KP878-R: CTTTCTTCTGCCCACTGTTG | KV1615-R: GGGCGTGGCTTTTTTCATCG | KmtnC-R: AGCGGGTGAACGTCGATAC | |||||
| phosphohydrolase | thiopurine S-methyltransferase | phosphopentane phosphatase ( | |||||
| 2 | M-PCR-3 | KP888-F: AAGCAAGCCAGAACAGAAAG | 888 | KV1000-F: CTGGGATGTGGCAATGGTG | 438 | KmtnC-F: CCGCCGACCTTATCACTAC | 340 |
| KP888-R: ACTTCGGTTTTATCCAGGTC | KV1000-F: AAACTGCGCCTGCTGTATC | KmtnC-R: AGCGGGTGAACGTCGATAC | |||||
aMultiplex-PCR conditions used under the oligonucleotides combinations. 1: 5pmol/reaction of K. variicola and Klebsiella spp, 25pmol/reaction of K. pneumoniae; 2: 25 pmol/reaction of K. pneumoniae, 5 pmol/reaction of K. variicola and 1 pmol/reaction of Klebsiella spp.
Figure 1The maximum-likelihood gene phylogenies of and . Bootstrapping of the gene tree was implemented to evaluate the support of the K. variicola and K. pneumoniae groups. The numbers next to the nodes are the bootstrap values, and the length of the branches has no meaning.
Figure 2Amplification by PCR of shared unique genes to and . A) Amplification of shared unique genes to K. variicola using the genomes of control strains such as K. pneumoniae ATCC 13883, K. variicola ATCC BAA-830 T, R. terrigena ATCC 33257, R. platicola ATCC 33531 and K. oxytoca ATCC 49134. B) Amplification of shared unique genes to K. pneumoniae using the genomes of control strains described above. Lane 1, ϕX174/Hae III; Lane 2, mtnC gene (KmtnC-F and -R oligonucleotides); Lane 3, phosphoglycerate mutase gene (KV770-F and -R oligonucleotides); Lane 4, thiopurine S-methyltransferase gene (KV1000-F and -R oligonucleotides); Lane 5, N-acetyltransferase gene (KV1615-F and -R oligonucleotides); Lanes 1 to 6, rpoB gene (CM7 and rpoB-M) in combination with oligonucleotides of shared unique genes K. variicola; Lane 7, rpoB oligonuclotides without DNA (CM7 and rpoB-M); Lane 8, Transferase gene (KP878-F and R oligonucleotides); Lane 9, phosphohydrolase gene (KP888-F and R oligonucleotides) (Table 1).
Figure 3Multiplex-PCR amplification of oligonucleotides combinations used for identification of . A) Lane 1, molecular weight 1 kb; Lane 2, oligonucleotide combination named M-PCR-1 (KV770-F/KV770-R, KP888-F/KP888-R and KmtnC-F/KmtnC-R); Lane 3, oligonucleotide combination named M-PCR-2 (KV1615-F/KV1615-R, KP878-F/KP878-R and KmtnC-F/KmtnC-R); Lane 4, oligonucleotide combination named M-PCR-3 (KV1000-F/KV1000-F, KP888-F/KP888-R and KmtnC-F/KmtnC-R) (Table 1). B) M-PCR-1 assayed on environmental endophytic K. variicola isolates. Lane 1, molecular weight ΦX174 DNA-Hae III; Lane 2, K. pneumoniae ATCC 13883 and K. variicola 801, DNA’s combination; Lane 3, K. variicola T29A; Lane 4, K. variicola 6A2; Lane 5, K. variicola CFNE 2006; Lane 6, K. variicola 3; Lane 7, K. variicola F2R9; Lane 8, K. variicola VI; Lane 9, negative control (without DNA).
Characteristics of endophytic and clinical isolates
|
|
|
|
|
|
|
|
| |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||
| 1109 | 1 | 1996 | Blood | NR | - | Negative |
| S | S | S | S | S | R |
|
|
|
| I | S | S | S | S |
| 801 | 2 | 1996 | Blood | A | + | SHV-2a |
|
| S | S |
| S | S |
|
|
|
|
| S | S | S | S |
| 803 | 2 | 1996 | Blood | A | + | SHV-2a |
|
| S | I |
| S | S |
| I | S |
|
| S | S | S | S |
| 804 | 2 | 1996 | Blood | A | + | SHV-2a |
|
| S | S |
| S | S |
| I | S |
|
| S | S | S | S |
| 805 | 2 | 1996 | Blood | A | + | SHV-2a |
|
| S | S |
| S | S |
| I | S |
|
| S | S | S | S |
| 806 | 2 | 1996 | Blood | A | + | SHV-2 |
|
| S | S |
| S | S |
| I | S |
|
| S | S | S | S |
| 807 | 2 | 1996 | Blood | A | + | SHV-2a |
|
| S | S |
| S | S |
|
| S |
|
| S | S | S | S |
| 808 | 2 | 1996 | Blood | A | + | SHV-2a |
|
|
| S |
| S | S |
| I | I |
|
| S | S | S | S |
| 809 | 2 | 1996 | Blood | A | + | SHV-2a |
|
|
| S |
| S | I |
|
|
|
|
| S | S | S | S |
| 811 | 2 | 1996 | Blood | A | + | SHV-2a |
|
|
| S |
| S | S |
|
| I |
|
| S | S | S | S |
| 812 | 2 | 1996 | Blood | A | + | SHV-2a |
|
|
| S |
| S | S |
|
| I |
|
| S | S | S | S |
| 1171 | 1 | 1998 | Catheter | NR | - | Negative |
| S | S | S | S | S | S | S | S | S | S | I | S | S | S | S |
| 1258 | 3 | 1999 | Blood | NR | + | SHV-5 |
|
|
| I |
| S |
| S | S |
|
|
| S | S | S | S |
| 06-268 | 4 | 2007 | Abscess | NR | + | CTX M- 15 |
|
| S | S | S | S |
|
|
| S | S | I | S | S | S | S |
| 8917 | 5 | 2011 | sputum | NR | - | Negative |
| S | S | S | S | S | S | S | S | S | S | S | S | S | S | S |
| 9635 | 6 | 2011 | Catheter | NR | - | Negative |
| S | S | S | S | S | S |
|
| S | S | I | S | S | S | S |
| 9351 | 6 | 2012 | Secretion | NR | - | Negative |
| S | S | S | S | S | S | S | S | S | S | I | S | I | S | S |
| 9352 | 6 | 2012 | Secretion | NR | - | Negative |
| S | S | S | S | S | S | S | S | S | S | S | S | S | S | S |
| 9353 | 6 | 2012 | Biliary liquids | NR | - | Negative |
| S | S | S | S | S | S | S | S | S | S | I | S | S | S | S |
| 4880 | 6 | 2013 | Blood | NR | - | Negative |
| S | S | S | S | S | S | S | S | S | S | I | S | I | S | S |
| 9326 | 6 | 2013 | Secretion | NR | - | Negative |
| S | S | S | S | S | S | S | S | S | S | S | S | S | S | S |
| 9387 | 6 | 2013 | Secretion | NR | - | Negative |
| S | S | S | S | S | S | S | S | S | S | I | S | S | S | S |
| 9388 | 6 | 2013 | Urine | NR | - | Negative |
| S | S | S | S | S | S | S | S | S | S | I | S | S | S | S |
| 9925 | 7 | 2013 | Abscess | NR | - | Negative |
| S | S | S | S | S | S | S | S | S | S | I | S | S | S | S |
| F2R9 | NA | 2003 | Banana root | NR | - | Negative |
| S | S | S | S | S | S | S | S | S | S | S | S | S | S | S |
| T29A | NA | 2003 | Sugar cane stem | NR | - | Negative |
| S | S | S | S | S | S | S | S | S | S | S | S | S | S | S |
| 6A2 | NA | 2003 | Banana leaves | NR | - | Negative |
| S | S | S | S | S | S | S | S | S | S | S | S | S | S | S |
| VI | NA | 2003 | Banana stem | B | - | Negative |
| S | S | S | S | S | S | S | S | S | S | S | S | S | S | S |
| 3 | NA | 2003 | Maize shoots | B | - | Negative |
| S | S | S | S | S | S | S | S | S | S | S | S | S | S | S |
| CFNE-2006 | NA | 2003 | Rice roots | NR | - | Negative |
| S | S | S | S | S | S | S | S | S | S | S | S | S | S | S |
aHospitlas: 1, Hospital de Niño y del Adolesente Morelense (HNAM); 2, Hospital del Niño de Tabasco (HNT);; 3, Hospital Infantil de Mexico (HIM); 4, Centro Regional de Control de Enfermedades Infecciosas (CRCEI); 5, Clinica del ISSSTE-Morelos (CHM); 6, Hospital Civil de Guadalajara (HCG); 7, Hospital Manuel Gea Gonzalez (HMGG).
bR = Resistant; I = Intermediate; S = Susceptible, according to CLSI15.
Abbreviations: Amoxicillin, AMX; Cephalothin, CF; Cefoxitin, FOX; Cefuroxime, CXM; Piperaciline, PIP; Piperaciline/Tazobactam, TZP; Aztreonam, ATM; Cefotaxime, CTX; Ceftazidime, CAZ, Gentamicin, GM; Amikacin, AMK; Ticarcillin, TIC; Tetracycline, TET; Nalidixic Acid, NAL; Ciprofloxacine, CIP; Levofloxacin, LUX.
Figure 4The maximum-likelihood phylogeny of the sequences. The tree was rooted with the sequences from Escherichia coli K-12 MG1655 and Salmonella enterica Ty21. To evaluate the support of the nodes, a bootstrap analysis of 100 replicates was conducted. For clarity, only the bootstrap values for the main groups are shown. The scale bar represents substitutions per site.
Figure 5PFGE and dendrogram analysis that includes and isolates. The figure shows the isolate (environmental and clinical), species, hospital and city, origin of sample, PFGE pattern and ESBL-producer phenotype.